Advances in measles virus for cancer therapy.
- Author:
Duo ZHOU
1
;
Zheng-yan ZHAO
1
Author Information
1. Pediatric Health Care Department, the Children's Hospital Zhejiang University School of Medicine, Hangzhou 310003, China.
- Publication Type:Journal Article
- MeSH:
Clinical Trials, Phase I as Topic;
Humans;
Measles virus;
Neoplasms;
therapy;
Oncolytic Virotherapy
- From:
Journal of Zhejiang University. Medical sciences
2015;44(4):458-464
- CountryChina
- Language:Chinese
-
Abstract:
Oncolytic virotherapy is a novel cancer therapy. Vaccine-attenuated strains of measles virus(MV)is an ideal candidate for oncolytic virotherapy which has an excellent safety record. Vaccine-attenuated MV uses CD46 and Nectin-4 molecule as major entry receptors into cells. Vaccine-attenuated MV can selectively infect and kill a wide variety of cancer cells in vitro and in vivo. With the development of molecular cloning, scientists have successfully rescued cDNA of vaccine-attenuated MV and increased its oncolytic efficiency with molecular engineering techniques. Phase I clinical trials of virotherapy for ovarian cancer and multiple myeloma with vaccine-attenuated MV are underway. The preliminary results indicate the promising antitumor potential of vaccine-attenuated MV.
